Latest News about GPCR
Recent news which mentions GPCR
Structure Therapeutics Stock Is Up 47%, but One Fund Just Fully Exited a $2.6 Million Position
May 10, 2026
Tickers
GPCR
From Motley Fool
Eli Lilly's Rare Weight Loss Data Miss Could Benefit Competitors
August 07, 2025
From Benzinga
From Benzinga
From Motley Fool
From Benzinga
The State of Weight Loss Drugs
March 10, 2025
From Motley Fool
Why Structure Therapeutics Stock Was Stumbling This Week
February 14, 2025
Tickers
GPCR
From Motley Fool
Viking Therapeutics, Structure Therapeutics Positioned As Key Pharma Partners For Weight Loss Products: Analyst
January 06, 2025
From Benzinga
Heico, Corvus Pharmaceuticals, Tesla And Other Big Stocks Moving Lower In Monday's Pre-Market Session
December 18, 2024
From Benzinga
Roche's Q3 Sales Surge Led By Ocrevus, Vabysmo, Urges Regulators To Block Novo Holdings' $16.5B Catalent Acquisition
October 23, 2024
From Benzinga
10 Health Care Stocks With Whale Alerts In Today's Session
October 16, 2024
From Benzinga
Prime Medicine, MINISO Group, Li Auto, Weibo And Other Big Stocks Moving Higher On Monday
September 30, 2024
From Benzinga
3 Promising Biotech Stocks for the Long-Term: August 2024
August 13, 2024
From InvestorPlace
Tickers
GPCR
From InvestorPlace
From InvestorPlace
From Motley Fool
Why ASLAN Pharmaceuticals Shares Are Trading Lower By Over 38%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
July 17, 2024
From Benzinga
From Benzinga
ASML Reports Q2 Results, Joins Spirit Airlines And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
July 17, 2024
From Benzinga
From InvestorPlace
The 3 Smartest Biotech Stocks to Buy With $5K Right Now
June 28, 2024
From InvestorPlace
From Motley Fool
Structure Therapeutics Stock Could Rocket 87% Higher, According to 1 Wall Street Analyst. Is It Time to Buy?
June 11, 2024
From Motley Fool
Structure Therapeutics' Stock Is Soaring on the Promise of Its Wegovy Competitor, but Is It a Buy?
June 09, 2024
From Motley Fool
From InvestorPlace
Tickers
GPCR
From InvestorPlace
Structure Therapeutics' Obesity Candidate Is ' Very Competitive' To Eli Lilly's Orforglipron, Analyst Says
June 03, 2024
From Benzinga
From Benzinga